Elanco is a division of Eli Lilly and Company, provides product and knowledge services to improve animal health in more than 70 countries around the world.
The company announced the U.S.FDA approval of Credelio® (lotilaner).
Credelio is a new monthly oral tick and flea treatment that is easy on dogs, but tough on ticks and fleas.
This new tick and flea option for dogs contains the patented active ingredient lotilaner, which targets the nervous system receptors of ticks and fleas, not dogs.
Credelio is a small, tasty2 chewable tablet approved for puppies and dogs eight weeks of age and older and 4.4 pounds and greater.
In a field study, 100 percent of Credelio tablets were administered successfully and dogs accepted 94 percent of them when offered by hand, in an empty bowl, or with food.
Credelio is also well accepted by a broad range of dog breeds.
In clinical studies, Credelio killed 100 percent of fleas within 12 hours for the entire month.
Elanco supports veterinarians with a wide range of parasiticide solutions.
